Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report

Wenxian Wang; Zhengbo Song; Yiping Zhang

doi:10.1111/1759-7714.12298

Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report

Thorac Cancer. 2016 Apr 26;7(3):355-7. doi: 10.1111/1759-7714.12298. Epub 2015 Jul 29.

Authors

Wenxian Wang¹, Zhengbo Song², Yiping Zhang²

Affiliations

¹ Department of Chemotherapy Zhejiang Cancer Hospital Hangzhou China.
² Department of Chemotherapy Zhejiang Cancer Hospital Hangzhou China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou China.

Abstract

Squamous cell lung cancer (SCC) presenting with anaplastic lymphoma kinase (ALK) translocation is rare. We present a case of ALK gene translocation-SCC in which a remarkable tumor response to crizotinib was achieved after the failure of prior chemoradiotherapy. Considering this remarkable response, we conclude that ALK testing in female non-smokers or in any patient unresponsive to the initial regimen of chemotherapy, is recommended for SCC patients.

Keywords: Crizotinib; EML4‐ALK; squamous cell lung cancer.